In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow